Investigation of 2 models to set and evaluate quality targets for Hb A1c: Biological variation and sigma-metrics

Clinical Chemistry

Volumn 61, Issue 5, 2015, Pages 752-759

  Weykamp, Cas ^a   John, Garry ^b   Gillery, Philippe ^c   English, Emma ^d   Ji, Linong ^e   Lenters Westra, Erna ^f,g   Little, Randie R ^h   Roglic, Gojka ⁱ   Sacks, David B ^j   Takei, Izumi ^k  

^a Queen Beatrix Hospital   (Netherlands)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f ISALA HOSPITAL   (Netherlands)

^g European Reference Laboratory for Glycohemoglobin   (Netherlands)

^h University of Missouri   (United States)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k BUILDING RESEARCH INSTITUTE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BIOLOGICAL VARIATION MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LABORATORY; MATHEMATICAL MODEL; PROGRAM EVALUATION; QUALITY CONTROL; SIGMA METRICS MODEL; STANDARDIZATION; BIOLOGICAL MODEL; HUMAN; METABOLISM; STANDARDS;

HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LABORATORIES; MODELS, BIOLOGICAL;

EID: 84929000266     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.235333     Document Type: Article

References (23)

1. Task Force on Implementation of HbA1c Standardization (Integrated Project) (TF-HbA1c). www.ifcc.org/executive-board-and-council/eb-task-forces/task-forcehba1c (Accessed April 2015).
2. Westgard JO, Carey RN, Wold S. Criteria for judging precision and accuracy in method development and evaluation. Clin Chem 1974;20:825-33.
3. Fraser CG, Hyltoft Petersen P, Libeer JC, Ricos C. Proposal for setting generally applicable quality goals solely based on biology. Ann Clin Biochem 1997;34:8-12.
4. Bais R, Armbruster D, Jansen RTP, Klee G, Panteghini M, Passarelli J, et al. Defining acceptable limits for the metrological traceability of specific measurands. Clin Chem Lab Med 2013;51:973-9.
5. Westgard JO, Westgard SA. Total analytical error: from concept to application. www.aacc.org/publications/cln/articles/2013/september/total-analytic-error (Accessed August 2014).
6. Kenny D, Fraser CG, Hyltoft Petersen P, Kallner A. Strategies to set global analytical quality specifications in laboratory medicine: consensus agreement. Scand J Clin Lab Invest 1999;59:585.
7. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement: the American Diabetes Organization, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007;30:2399-400.
8. Weykamp CW, Mosca A, Gillery P, Panteghini M. The analytical goals for hemoglobin A(1c) measurement in IFCC units and National Glycohemoglobin Standardization Program Units are different. Clin Chem 2011;57:1204-6.
9. American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care 2011;34(Suppl 1):S11-61.
10. Westgard QC. Quality requirements: minimum specifications from Biological Variation database. www.westgard.com/minimum-biodatabase1.htm (Accessed August 2014).
11. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents. http://www.nice.org.uk/guidance/cg87/resources/cg87-type-2-diabetes-newer-agents-a-partial-update-of-cg66-short-guideline2 (Accessed October 2014).
12. American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care 2010;33(Suppl 1):S23.
13. 1c) using an accurately designated protocol and an assay traceable to the IFCC reference system. Clin Chim Acta 2011;412:1412-6.
14. Carlsen S, Petersen PH, Skeie S, Skadberg O, Sandberg S. Within-subject biological variation of glucose and HbA(1c) in healthy persons and in type 1 diabetes patients. Clin Chem Lab Med 2011;49:1501-7.
15. 1c: consequences for diagnosing diabetes mellitus. Clin Chem 2014;60:1570-2.
16. College of American Pathologists (CAP) GH2 survey data. www.ngsp.org/CAPdata.asp (Accessed August 2014).
17. Miller WG, Jones GR, Horowitz GL, Weykamp C. Proficiency testing/external quality assessment: current challenges and future directions. Clin Chem 2011;57:1670-80.
18. The European Reference Laboratory for Glycohemoglobin. www.euroreflab.com (Accessed August 2014).
19. Aarsand AK, Roraas T, Sandberg S. Biological variation: reliable data is essential. Clin Chem Lab Med 2015;53:153-4.
20. Roraas T, Petersen PH, Sandberg S. Confidence intervals and power calculations for within-person biological variation: effect of analytical imprecision, number of replicates, number of samples, and number of individuals. Clin Chem 2012;58:1306-13.
21. 1c for diabetes diagnosis: predictive values of one test and importance of analytical bias and imprecision. Clin Chem Lab Med 2014;52:1069-77.
22. Report to Danish Health and Medicine Authority by DEKS (in Danish). www.dskb.dk/media/documents/VUK%20HbA1c.doc (Accessed August 2014).
23. Hyltoft Petersen P, Klee GG. Influence of analytical bias and imprecision on the number of false positive results using guideline-driven medical decision limits. Clin Chim Acta 2014;430:1-8.